MovDisordV3, Main, Exploration, bibRecord, 001207

Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's Disease

Identifieur interne : 001207 ( Main/Exploration ); précédent : 001206; suivant : 001208

Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's Disease

Auteurs : Lissa S. Brod [États-Unis] ; Jason L. Aldred [États-Unis] ; John G. Nutt [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0248761

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Dose forte, Carbidopa, Essai clinique, Lévodopa.

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Area Under Curve, Carbidopa, Carbidopa (administration & dosage), Carbidopa (pharmacokinetics), Carbidopa (therapeutic use), Clinical trial, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, High dose, Humans, Levodopa, Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Treatment Outcome.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa.
- chemical , pharmacokinetics : Antiparkinson Agents, Carbidopa.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa.
- drug therapy : Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Area Under Curve, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Treatment Outcome.

Abstract

Recommended doses of carbidopa are 75-200 mg/day. Higher doses could inhibit brain aromatic amino-acid decarboxylase and reduce clinical effects. We compared 4-week outpatient treatments with carbidopa (75 and 450 mg/day) administered with _L-dopa on the subjects' normal schedule. After each treatment phase, subjects had two 2-hour _L-dopa infusions. The first infusion examined the effects of carbidopa doses administered the preceding 4 weeks, and the second infusion determined the acute effects of the two dosages of carbidopa. The antiparkinsonian effects and _L-dopa and carbidopa plasma concentrations were monitored during the infusions. Twelve subjects completed the study. Carbidopa concentrations were eight times higher after the high-carbidopa phase. Area under the curve (AUC) for clinical ratings did not differ for the four _L-dopa infusions, although AUC for plasma _L-dopa was modestly increased with 450 mg of carbidopa. Nine subjects reported that the high-carbidopa outpatient phase was associated with greater response to _L-dopa. Doses of 450 mg/day of carbidopa did not reduce the responses to _L-dopa infusion, extending the safe range of carbidopa to 450 mg/day.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707928

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's Disease</title>
<author><name sortKey="Brod, Lissa S" sort="Brod, Lissa S" uniqKey="Brod L" first="Lissa S." last="Brod">Lissa S. Brod</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Portland VA Medical Center Parkinson Disease Research, Education and Clinical Center</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oregon Health & Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aldred, Jason L" sort="Aldred, Jason L" uniqKey="Aldred J" first="Jason L." last="Aldred">Jason L. Aldred</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Portland VA Medical Center Parkinson Disease Research, Education and Clinical Center</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oregon Health & Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Portland VA Medical Center Parkinson Disease Research, Education and Clinical Center</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oregon Health & Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0248761</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0248761 INIST</idno>
<idno type="RBID">Pascal:12-0248761</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000179</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002B35</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000280</idno>
<idno type="wicri:doubleKey">0885-3185:2012:Brod L:are:high:doses</idno>
<idno type="wicri:Area/Main/Merge">001259</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707928</idno>
<idno type="RBID">PMC:3707928</idno>
<idno type="wicri:Area/Pmc/Corpus">000264</idno>
<idno type="wicri:Area/Pmc/Curation">000264</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000212</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000D99</idno>
<idno type="wicri:Area/PubMed/Curation">000D99</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F39</idno>
<idno type="wicri:Area/Ncbi/Merge">003631</idno>
<idno type="wicri:Area/Ncbi/Curation">003631</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003631</idno>
<idno type="wicri:doubleKey">0885-3185:2012:Brod L:are:high:doses</idno>
<idno type="wicri:Area/Main/Merge">000F30</idno>
<idno type="wicri:Area/Main/Curation">001207</idno>
<idno type="wicri:Area/Main/Exploration">001207</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's Disease</title>
<author><name sortKey="Brod, Lissa S" sort="Brod, Lissa S" uniqKey="Brod L" first="Lissa S." last="Brod">Lissa S. Brod</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Portland VA Medical Center Parkinson Disease Research, Education and Clinical Center</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oregon Health & Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aldred, Jason L" sort="Aldred, Jason L" uniqKey="Aldred J" first="Jason L." last="Aldred">Jason L. Aldred</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Portland VA Medical Center Parkinson Disease Research, Education and Clinical Center</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oregon Health & Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Portland VA Medical Center Parkinson Disease Research, Education and Clinical Center</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Oregon Health & Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (pharmacokinetics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Area Under Curve</term>
<term>Carbidopa</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (pharmacokinetics)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Clinical trial</term>
<term>Cross-Over Studies</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>High dose</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Area Under Curve</term>
<term>Cross-Over Studies</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Dose forte</term>
<term>Carbidopa</term>
<term>Essai clinique</term>
<term>Lévodopa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recommended doses of carbidopa are 75-200 mg/day. Higher doses could inhibit brain aromatic amino-acid decarboxylase and reduce clinical effects. We compared 4-week outpatient treatments with carbidopa (75 and 450 mg/day) administered with <sub>L</sub>
-dopa on the subjects' normal schedule. After each treatment phase, subjects had two 2-hour <sub>L</sub>
-dopa infusions. The first infusion examined the effects of carbidopa doses administered the preceding 4 weeks, and the second infusion determined the acute effects of the two dosages of carbidopa. The antiparkinsonian effects and <sub>L</sub>
-dopa and carbidopa plasma concentrations were monitored during the infusions. Twelve subjects completed the study. Carbidopa concentrations were eight times higher after the high-carbidopa phase. Area under the curve (AUC) for clinical ratings did not differ for the four <sub>L</sub>
-dopa infusions, although AUC for plasma <sub>L</sub>
-dopa was modestly increased with 450 mg of carbidopa. Nine subjects reported that the high-carbidopa outpatient phase was associated with greater response to <sub>L</sub>
-dopa. Doses of 450 mg/day of carbidopa did not reduce the responses to <sub>L</sub>
-dopa infusion, extending the safe range of carbidopa to 450 mg/day.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Oregon</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Oregon"><name sortKey="Brod, Lissa S" sort="Brod, Lissa S" uniqKey="Brod L" first="Lissa S." last="Brod">Lissa S. Brod</name>
</region>
<name sortKey="Aldred, Jason L" sort="Aldred, Jason L" uniqKey="Aldred J" first="Jason L." last="Aldred">Jason L. Aldred</name>
<name sortKey="Aldred, Jason L" sort="Aldred, Jason L" uniqKey="Aldred J" first="Jason L." last="Aldred">Jason L. Aldred</name>
<name sortKey="Brod, Lissa S" sort="Brod, Lissa S" uniqKey="Brod L" first="Lissa S." last="Brod">Lissa S. Brod</name>
<name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001207 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001207 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0248761
   |texte=   Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's Disease

Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.